Tumblelog by Soup.io
Newer posts are loading.
You are at the newest post.
Click here to check if anything new just came in.
todcgru

Mdxhealth Licenses Epigenetic Technology To Oncgnostics Gmbh For Cervical Cancer Test - Yahoo Finance

"We are excited about oncgnostics epigenetic GynTect(R) test, which will aid in the diagnosis and treatment of women with cervical cancer." About oncgnostics GmbH Founded as a spin-off from the University Womens' Hospital Jena, oncgnostics focuses on in vitro diagnostic tests for the early and accurate detection of cancer utilizing proprietary epigenetic biomarkers. The diagnostic products will allow earlier detection of more cancer cases and thus contribute to the improvement of therapeutic success. The initial product developed, GynTect (R), allows for the rapid and reliable detection of cervical precancerous lesions and visit site cancer. Through strategic alliances with other industry leaders, oncgnostics aims to extend its reach around the world. More information is available at http://abigailsite.beeplog.com www.oncgnostics.com and through contact@oncgnostics.com . About MDxHealth (R) MDxHealth is a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment. The company's tests are based on proprietary gene methylation (epigenetics) technology and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy.
More: http://finance.yahoo.com/news/mdxhealth-licenses-epigenetic-technology-oncgnostics-070603262.html

Don't be the product, buy the product!

Schweinderl